Exposure of platelets to shear stress leads to aggregation in the absence of exogenous agonists. We 
platelet aggregation may underlie the pathology associated with vascular occlusion (3) (4) (5) (6) (7) . During thrombogenesis, circulating platelets become localized on altered vascular surfaces or exposed tissues (reviewed in 8) and become activated through a complex series ofbiochemical events (reviewed in 9). Activated platelets, then, adhere and aggregate to one another forming the thrombus mass, a process that has an absolute requirement for the membrane glycoprotein (GP)' Ilb-IlIa complex (reviewed in 10). Different experimental models have been used to investigate the molecular mechanisms of platelet adhesion and aggregation. Such models, however, reproduce only partially the complex series of events occurring during thrombogenesis in the intact organism; consequently, the results obtained may be limited in their significance by the specific set of conditions prevalent in a particular test system. Nevertheless, findings obtained with the aggregometer (I 1), a commonly used device for the study of platelet function based on the response to exogenous agonists, have favored the prevalent concept that fibrinogen is the essential adhesive protein mediating platelet-to-platelet contact ( 12, 13). In the aggregometer, however, platelet-rich plasma is subjected to shear forces, due to stirring, that differ considerably from those existing in the circulation, so that the possible role of Theological parameters in platelet aggregation cannot be properly evaluated.
Blood circulating in vessels is exposed to shear stress caused by the force necessary to produce flow; the difference in velocity between layers situated at varying distances from the vessel wall determines the shear rate, which is directly proportional to the shear force and inversely proportional to the viscosity of blood. Studies performed under controlled conditions of high shear stress, such to mimic the Theological situation existing in certain districts of the arterial circulation, have suggested that adhesive ligands distinct from fibrinogen may participate in platelet aggregation (14) (15) (16) (17) (18) . With a series of key observations, Moake et al. (14, 17) and Peterson et al. (16) introduced the concept that von Willebrand factor (vWf) may have a crucial role in high shear induced aggregation. Indeed, vWf binding to the GP Ib-IX complex was shown to be an essential step in the process, whereas the nature ofthe adhesive protein, or proteins, engaged in the interaction with GP IIb-IIIa, absolutely required for aggregation, could not be determined. Fibrinogen and fibronectin, in addition to vWf, were considered obvious candidates for the role.
In view of these uncertainties, we undertook these studies to identify the adhesive proteins involved in platelet aggrega- (19, 20) . These results underline the potential importance of vWf in acute arterial thrombosis.
Methods
Patients and controls. All human subjects who participated in these studies were aware ofthe experimental nature ofthe research and gave their informed consent, in accordance with the Declaration of Helsinki. Normal controls were staff members of Keio University with no personal or familial history of abnormal bleeding symptoms. The patients with Glanzmann's thrombasthenia, Bernard-Soulier syndrome, afibrinogenemia, and severe von Willebrand disease fulfilled all the accepted criteria for the diagnosis of these disorders. In particular, the two thrombasthenic patients had no measurable platelet membrane GP Ilb-IlIa complex; the two patients with Bernard-Soulier syndrome had no measurable platelet membrane GP Ib; the patient with afibrinogenemia had < 10 gg/ml of plasma fibrinogen; and the two patients with severe von Willebrand disease had < 0.1% of normal vWf plasma levels. All patients and controls denied consuming drugs known to interfere with platelet function for the week preceding the studies.
Modified viscometerfor measuring shear-induced platelet aggregation. The cone and plate viscometer used to measure platelet aggregation induced by varying shear stress was similar to the one described previously (21) . It consisted essentially of a helium-neon laser light source at 633 nm, a thermostated cone-plate streaming chamber, and a photocounting unit, the output of which, digitized through an appropriate interface, was analyzed and stored in a microcomputer unit.
Shear rate (-t) was calculated according to the formula y = 6N/O, where N is the rotational speed of the cone and 0 is the cone angle. In the device used for these studies the cone angle was 10 and the distance between the cone and the plate was adjusted with an electronic sensor rather than with the mechanical micrometer screw described before (21) . This allowed for a more precise and reproducible measurement of the shear forces applied to the samples. Shear stress was calculated multiplying the shear rate by the viscosity of the fluid, assumed to be 1.2 centipoise for all the platelet-rich plasma samples tested. Platelet suspensions exhibited an inverse linear relationship between the single platelet count and the logarithm of transmitted light intensity. This is expressed by the equation log (Ij11) = -k x 1 x c, where It and I, are the transmitted and incident light intensity, k is the absorption coefficient, I is the effective light path length, and c is the single platelet count. Thus, A log I expresses the extent of platelet aggregation, namely the decrease in single platelet count, since A log I = log ItlI -log It/I, = k X l X (Cb-Ca), where I. and Itbare transmitted light intensities, and Ca and Cb are single platelet counts, after (a) and before (b) application of shear stress, respectively. Changes in the optical density of the platelet suspension corresponded to the occurrence ofplatelet-to-platelet interactions leading to the formation of aggregates, as shown by electron microscopic analysis (21) . Measurement ofplatelet aggregation. The anticoagulant used for blood collection was either trisodium citrate (0.0 I M final concentration), which acts to decrease the available concentration ofCa2" necessary for several reactions that lead to clotting (2) , or hirudin (Seikagaku Kogyo, Tokyo, Japan), a potent and specific thrombin inhibitor obtained from the saliva ofthe common leech, Hirudo medicinalis. Hirudin was used at the final concentration of 200 U/ml (1 U of hirudin neutralizes the activity of 1 NIH unit of a-thrombin). Hirudin rapidly and irreversibly blocks the fibrinogen clotting activity ofthrombin (reviewed in 22) but has no effect on the concentration of Ca2" or other divalent cations. Platelet-rich plasma was prepared by centrifugation at 100 g for 15 min at 22-250C; the platelet count was adjusted to 3 x I054dI using homologous platelet-poor plasma, obtained by centrifugation of blood at 3,000 g for 20 min. When studying patients with Bernard-Soulier syndrome, who have thrombocytopenia, the platelet count in the control normal platelet-rich plasma was adjusted to the same values obtained in the thrombocytopenic patients, -1 X 103/1L.
For measuring shear-induced aggregation, 400 gl of platelet-rich plasma was applied onto the surface of the polymethylmethacrylate plate and exposed to varying shear stress for 5 min at 370C. Aggregation was monitored continuously by recording the intensity ofthe light transmitted through the platelet suspension from the beginning of application of the shear forces. Agonist-induced platelet aggregation was measured in an aggregometer (Chrono-Log Corp., Havertown, PA), as described previously (23) . In this case, aggregation was expressed as percent light transmittance, after adjusting the aggregometer at 0% transmittance with platelet-rich plasma and 100% transmittance with platelet-poor plasma.
Monoclonal antibodies. All the monoclonal antibodies used in these studies were obtained and characterized as described previously.
LJ-Ibl is a murine IgG, obtained by immunization with purified GP Ib-IX complex (24) . This antibody reacts with the amino terminal 45-kD domain of GP Iba containing the vWf-binding domain (25, 26) ; it inhibits completely vWf binding to platelets mediated by ristocetin (24) , but has no effect on the binding to GPIIb-IIIa induced by thrombin. LJ-CP8 is a murine IgG1, obtained by immunization with washed human chymotrypsin-treated platelets; it reacts with the GP Ilb-IIIa complex (27) and completely blocks the interaction of vWf, fibrinogen, fibronectin, and vitronectin with GP Ilb-IIIa. LJ-152B/6 is a murine IgG, obtained by immunization with a synthetic peptide containing the Arg-Gly-Asp sequence and flanking residues of vWf (28) . This antibody reacts specifically with the GP Ilb-Illa binding site of vWf; has no cross-reactivity with fibrinogen, fibronectin, or vitronectin, even though all these molecules contain at least one Arg-Gly-Asp sequence homologous to that recognized by the antibody in vWf; and selectively inhibits vWf binding to GP IIb-IIIa (28) . All IgG were purified on protein-A Sepharose (Sigma Chemical Co., St. Louis, MO) as described (29) , then dialyzed against a buffer composed of 20 mM 4-(2-hydroxyethyl)-l-piperazine ethane sulfonic acid (Hepes) and 150 mM NaCI, pH 7.4 (Hepes buffer), and stored at -70°C until used.
Results
Aggregation in platelet-rich plasma containing trisodium citrate as anticoagulant was absent in two patients with Glanzmann's thrombasthenia, i.e., deficient in GP Ilb-IIla, both at low (12 dyn/cm2) and high shear (108 dyn/cm2); in contrast, in two patients with Bernard-Soulier syndrome, i.e., deficient in GP Ib-IX, aggregation was normal at low but absent at high shear ( Fig. 1) . As typically expected in these cases, ADP-induced aggregation was absent in the thrombasthenic patients but-normal in the Bernard-Soulier patients (not shown). Contrasting results were also found in one patient with afibrinogenemia, in whom aggregation was absent at low shear but normal at high shear, and in two patients with a complete deficiency of vWf, in whom aggregation was normal at low shear but absent at high shear ( Fig. 1) . Again, as expected in these cases, ADPinduced aggregation was absent in the afibrinogenemic patient but normal in the two with severe von Willebrand disease (not shown). Note that the extent of aggregation observed at low shear forces was considerably less than at higher shear forces (compare the scales for A log I in Fig. 1 ).
To explore in more detail the effect of shear forces on platelet aggregation, a gradient varying between 6 and 108 dyn/cm2 was applied to citrated platelet-rich plasma over a 5-min period. After an initial 15 s at 6 dyn/cm2, the gradient varied between 6 and 12 dyn/cm2 in 90 s (Fig. 2) (Fig. 2) .
To confirm the distinct role of different platelet membrane glycoproteins and plasma adhesive proteins in aggregation induced by varying shear stress, the effect of specific monoclonal antibodies was tested at low (12 dyn/cm2) and high shear stress (108 dyn/cm2), as well as in the shear gradient between 6 and 108 dyn/cm2 described above. The aggregation observed when low shear stress was applied to citrated platelet-rich plasma was inhibited only by the anti-GP Ilb-Illa monoclonal antibody LJ-CP8, which completely blocks the interaction of all adhesive proteins with this site; no inhibition was observed either with the anti-GP Tb antibody J-Tb 1, which inhibits vWf binding to GP Tb, or with the anti-vWf monoclonal antibody LI-152B/6, which selectively inhibits binding to GP IIb-IIIa by blocking specifically the function of the Arg-Gly-Asp sequence in vWf (Fig. 3) . These results exclude a role for vWf in platelet aggregation under low shear force. In contrast, the aggregation Fig. 1 ) or at varying shear force (see Fig. 2 ), as indicated (the broken line in the panels to the right indicates the change in shear force over time). Note that only the anti-GP Ilb-Illa antibody inhibited aggregation induced by low shear force, either applied continuously or in the initial part of the gradient, whereas all three antibodies inhibited high shear-induced aggregation. The concentration used for each antibody was known to give maximal binding to the corresponding target antigen.
induced by high shear stress was inhibited completely by each of the three antibodies (Fig. 3) , suggesting that under these conditions vWf-binding to both its platelet receptors, and particularly binding to GP lb-IIla through the Arg-Oly-Asp sequence, is necessary for aggregation to occur. The results observed with the shear gradient were concordant with those observed at constant shear stress values, since the first wave of aggregation was inhibited only by the nonselective anti-GP IlbIlIa antibody, while the second was inhibited also by the anti-GP lb antibody and the anti-vWF antibody specifically inhibiting binding to GP Ilb-Illa (Fig. 3) .
The experiments reported to this point are compatible with the hypothesis that the binding of vWf to both GP lb and GP Ilb-ila is necessary to support aggregation under high shear forces and in the absence of exogenous agonists. Since the direct binding of soluble vWf to GP lb may be inhibited by Ca2" ions, as shown previously with asialo vWF (30) , shear-induced aggregation was also tested using platelet-rich plasma containing hirudin as anticoagulant, and thus at normal blood concentrations ofionized calcium. These experiments were performed to rule out the possibility that the results described here, as well as those obtained by others (14, 16, 17) , might be artifacts caused by lower than normal divalent cation concentration. Indeed, the aggregation induced by low shear force in plasma containing citrate (Fig. 2) was practically absent in plasma containing hirudin as anticoagulant (Fig. 4) inhibited ADP-induced aggregation as measured in the aggregometer, while the anti-GP lb antibody had no inhibitory effect (Fig. 4) . Aggregation induced by high shear stress in the presence of physiologic ionized calcium concentrations was completely inhibited by the anti-vWf antibody that selectively blocks binding to GP lIb-IlIa but not to GP Ib, while the same antibody had no effect on ADP-induced aggregation measured in the aggregometer (Fig. 5 ). Because these experiments were performed using normal plasma containing all the circulating adhesive proteins and normal concentrations of divalent cations, the results indicate that vWf is the only adhesive protein in plasma necessary to support aggregation induced by high shear force, a function requiring interaction with both GP IlbIIIa, through the Arg-Gly-Asp sequence, and GP Ib-IX, through the specific binding site for this receptor.
Discussion
Our results characterize the distinct adhesive proteins and membrane receptors involved in platelet aggregation occurring under varying shear stress. In the absence of exogenous agonists, aggregation in platelet-rich plasma with low ionized calcium levels (containing 11 mM trisodium citrate) exhibits two distinct phases: (31, 32) , particularly with shear forces below 30 dyn/cm2 (17, 32). The possible role ofthromboxane A2, however, has been suggested by the observation that a thromboxane synthetase inhibitor can block fibrinogen-dependent shear-induced aggregation (32) . Indeed, activation ofthe arachidonate pathway occurs in human platelets brought in close proximity in media with low [Ca2+]0 (33), and this could explain why aggregation induced by low shear stress was negligible in plasma with normal divalent cation concentration. The exact mechanisms by which thromboxane A2 synthesis may be stimulated by shear stress, however, remain unknown at present. Another possibility is that shear stress affects the conformation and function of GP IIb-IIIa and/or fibrinogen, inducing binding of fibrinogen to unstimulated platelets in the absence of exogenous agonists. For example, it has been shown that fibrinogen insolubilized onto polystyrene beads can interact with GP Ilb-IIIa without prior activation ofplatelets (34) , and it is possible that shear stress affects the conformation of fibrinogen in a manner similar to that caused by adsorption onto a surface. The findings ofa previous study (32) suggested that fibrinogen is a necessary cofactor for aggregation induced by shear force values between 54 and 90 dyn/cm2. Our results are in apparent contradiction with those conclusions, since we have now found that aggregation at shear forces above 81 dyn/cm2 is independent of fibrinogen. In the viscometer used for the previous set ofexperiments, however, the distance between the cone and the plate was adjusted mechanically; thus, variations in this distance may have led to inaccurate estimation of the shear forces applied to the samples. In the modified viscometer used for the experiments described here, the distance was maintained within strict limits with an electronic sensor; thus, the shear forces applied to the samples could be calculated with more precision. However, both this study and the previous study agree that shear-induced aggregation mediated by fibrin- Experimental studies of platelet aggregation, like those reported here, are usually based on measuring the occurrence of interplatelet contacts in suspension. On the contrary, the process ofthrombus growth in the intact organisms involves platelet adhesion to exposed subendothelium followed by "aggregation" of incoming platelets to the adhering ones to form the thrombus mass (2) . Thus, during thrombogenesis in vivo, platelets become immobilized onto a surface rather than aggregating in suspension. Under high shear stress conditions, attachment ofplatelets to surface-bound vWf through GP Ib-IX is crucial for initial adhesion (44) . Our results suggest that this interaction, even in the absence of other agonists or activation ofclotting, may trigger a platelet response leading to expression ofthe binding function of GP lb-Illa which, by binding vWf from the surrounding medium, can strengthen the interplatelet contact to sustain the opposing effect of shear forces. One can envision a mechanism by which the interplatelet interaction leading to thrombus growth is initially GP Tb-dependent, but becomes progressively reinforced by expression of the binding function of GP Ilb-Illa. This hypothesis of a self-sustaining process involving two adhesion receptors and one adhesive ligand is consistent with the experimental findings, presented here and previously by others (16, 17) , that a block in vWf binding to either GP lb-IX or GP Ilb-Illa results in obliteration ofshear-induced aggregation. This hypothesis also implies that, under the particular conditions of high shear stress, platelet activation can follow the initial attachment mediated by vWf and GP lb. Indeed, vWfinteraction with GP lb has been shown to induce, in the absence ofany other exogenous agonists, functional activity of the GP Ilb-Illa receptor which, in turn, can support platelet aggregation (30, 45) . It remains to be understood how shear force above a threshold value can promote the initial binding of vWf to GP Tb, possibly through conformational changes of components of the platelet surface (16), and how this can affect the binding function and/or selectivity of GP Ilb-IIIa.
With regard to acute arterial occlusion, platelets in circulating blood may become exposed to shear stress values in excess of several hundred dyn/cm2, as in small arteries and arterioles partially obstructed by atherosclerotic processes or as a consequence of vasospasm (19, 20) . If, as suggested by our findings, vWf binding to GP lb-IX and GP lb-Illa becomes crucial in initiating and mediating the formation ofocclusive thrombi in stenosed atherosclerotic vessels, strategies directed at inhibiting these interactions may be useful in preventing thrombotic vascular occlusion. This approach may also provide selectivity and result in lesser antihemostatic consequences, ifother adhesive proteins, such as fibrinogen, support hemostatic plug formation at lower shear stress and/or in the presence of other platelet agonists.
